Misrouted cell surface receptors as a novel disease aetiology and potential therapeutic target: the case of hypogonadotropic hypogonadism due to gonadotropin-releasing hormone resistance

Bibliography

• CONN PM, CROWLEY WF: Gonadotropin-releasing hormone and its analogues. New Engl. J. Med. (1991) 324:93–103.
   PubMed Web of Science ®Google Scholar
• ULLOA-AGUIRRE A, TIMOSSI C: Biochemical and functional aspects of gonadotropin-releasing hormone and gonadotropins. RBM Online (2000) 1:48–62.
   Google Scholar
• ULLOA-AGUIRRE A, MAYA-NOSIEZ G, SODERLUND D, CONN PM: GnRH receptor gene, mutation of. In: Encyclopedia of Endocrinology and Endocrine Diseases. Martini L (Ed.), Academic Press, San Diego (2003). In Press.
   Google Scholar
• DE ROUX N, MILGROM E: Inherited disorders of GnRH and gonadotropin receptors. Mal Cell. Endocrirrol (2001) 179:83–87.
   PubMed Web of Science ®Google Scholar
• SEALFON SC, WEINSTEIN H, MILLAR RP: Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr. Rev (1997) 18:180–205.
   PubMed Web of Science ®Google Scholar
• ULLOA-AGUIRRE A, CONN PM: G protein-coupled receptors and the G protein family. In: Handbook of Physiology (Section 7) (Vol. I): Cellular Endocrinology Conn PM (Ed.), Oxford University Press, New York (1998):87–124.
   Google Scholar
• LIN X, JANOVICK JA, BROTHERS S, BLOMENROHR M, BOGERD J, CONN PM: Addition of catfish gonadotropin-releasing hormone (GnRH) receptor intracellular carboxyl-terminal tail to rat GnRH receptor alters receptor expression and regulation. Mol Endocfirrol. (1998) 12:161–171.
   PubMedGoogle Scholar
• •This study describes the effects of adding a C-terminal tail to the mammalian GnRHR.
   Google Scholar
• KOTTLER ML, LORENZO F, BERGAMETTI E COMMERCON P, SOUCHIER C, COUNIS R: Subregional mapping of the human gonadotropin-releasing hormone receptor (GnRH-R) gene to 4q between markers D45392 and D45409. Hum. Genet. (1995) 96:477–480.
   PubMed Web of Science ®Google Scholar
• •Study describing the localisation of the human GnRHR gene.
   Google Scholar
• ULLOA-AGUIRRE A, STANISLAUS D, JAN OVICK JA, CONN PM: Structure-activity relationships of G protein-coupled receptors. Arch. Med. Res. (1999) 30:420–435.
   PubMed Web of Science ®Google Scholar
• KOTTLER M-L, COUNIS R, BOUCHARD P: Mutations of the GnRH receptor gene: a new cause of autosomal-recessive hypogonadotropic hypogonadism. Arch. Med. Res. (1999) 30:481–485.
   PubMed Web of Science ®Google Scholar
• RADFORD SE, DOBSON CM: From computer simulations to human disease: emerging themes in protein folding. Cell (1999) 97:291–298.
   PubMed Web of Science ®Google Scholar
• BROOKS DA: Molecular chaperones of theER: their role in protein folding and genetic disease. Semirr. Cell Dev. Biol. (1999) 10:441–442.
   PubMed Web of Science ®Google Scholar
• SANDERS CR, NAGY JK: Misfolding ofmembrane proteins in health and disease: the lady or the tiger? Curr. Opin. Strucr Biol. (2000) 10:438–442.
   PubMed Web of Science ®Google Scholar
• BELLOTI V, MANGIONE P, STOPPINI M: Biological activity and pathological implications of misfolded proteins. Cell. Mal Life Sci. (1999) 55:977–991.
   PubMed Web of Science ®Google Scholar
• CAHILL M, CAHILL S, CAHILL K: Proteins wriggle. Biophys. 1 (2002) 82:2665-2670.
   Google Scholar
• HELENIUS A: Quality control in the secretory assembly line. Phil. Trans. R. Soc. Loud. (2001) 356:147–150.
   PubMed Web of Science ®Google Scholar
• ELLGAARD L, HELENIUS A: Quality control: towards an understanding at the molecular level. Curr. Opin. Cell Biol. (2001) 13:431–437.
   PubMed Web of Science ®Google Scholar
• HARTL FU, HAYER-HARTL M: Molecular chaperones in the cytosol: from nascent chain to folded protein. Science (2002) 295:1852–1858.
   PubMed Web of Science ®Google Scholar
• •• An updated review on molecular chaperones.
   Google Scholar
• ELLGAARD L: Setting the standards: quality control in the secretory pathway. Science (1999) 286:1882–1888.
   PubMed Web of Science ®Google Scholar
• MORELLO JP, PETÄJÄ-REPO UE, BICHET DG, BOUVIER M: Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol Sci. (2000) 21:466–469.
   PubMed Web of Science ®Google Scholar
• LUQUE I, LEAVITT SA, FREIRE E: The linkage between protein folding and functional cooperativity: two sides of the same coin? Ann. Rev Biophys. Biomol. Struct. (2002) 31:235–256.
   PubMedGoogle Scholar
• BRADY AE, LIMBIRD LE: G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell. Signal. (2002) 14:297–309.
   PubMed Web of Science ®Google Scholar
• DWYER ND, TROEMEL ER, SENGUPTA P, BARGMANN CI: Odorant receptor localization to olfactory cilia is mediated by ODR-4, a novel membrane-associated protein. Cell (1998) 93:455–466.
   PubMed Web of Science ®Google Scholar
• LIU D, BIENKOWSKA J, PETOSA C, COLLIER RJ, FU H, LIDDINGTON R: Crystal structure of the zeta isoform of the 14-3-3 protein. Nature (1995) 376:191–194.
   PubMed Web of Science ®Google Scholar
• SCHNEUWLY S, SHORTRIDGE RD, LARRIVEE DC, ONO T, OZAKI M, PAK WL: Drosophila ninaA gene encodes an eye-specific cyclophilin (cyclosporine A binding protein). Proc. Natl. Acad. Sci. USA (1989) 86:5390–5394.
   PubMed Web of Science ®Google Scholar
• SHIEH BH, STAMNES MA, SEAVELLO S, HARRIS GL, ZUKER CS: The ninaA gene required for visual transduction in Drosophila encodes a homologue of cyclosporin A-binding protein. Nature (1989) 338:67–70.
   PubMed Web of Science ®Google Scholar
• COLLEY NJ, BAKER EK, STAMNES MA,ZUKER CS: The cyclophilin homolog ninaA is required in the secretory pathway. Cell (1991) 67:255–263.
   PubMed Web of Science ®Google Scholar
• BAKER EK, COLLEY NJ, ZUKER CS: The cyclophilin homolog NinaA functions as a chaperone, forming a stable complex in vivo with its protein target rhodopsin. EMBO J. (1994) 13:4886–4895.
   PubMed Web of Science ®Google Scholar
• ROZELL TG, DAVIS DP, CHAT Y, SEGALOFF DL: Association of gonadotropin receptor precursors with the protein folding chaperone calnexin. Endocrinology (1998) 139:1588–1593.
   PubMed Web of Science ®Google Scholar
• MORELLO JP, SALAHPOUR A, PETAJA-REPO UE et al.: Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus. Biochemistry (2001) 40:6766–6775.
   PubMed Web of Science ®Google Scholar
• HOBBS HH, RUSSELL DW, BROWN MS, GOLDSTEIN JL: The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Ann. Rev. Genet. (1990) 24:133–170.
   PubMed Web of Science ®Google Scholar
• WELSH ML, SMITH AE: Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell (1993) 73:1251–1254.
   PubMed Web of Science ®Google Scholar
• DENNING GM, ANDERSON MP, AMARA JF, MARSHALL J, SMITH AE, WELSH MJ: Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature (1992) 358:761–764.
   PubMed Web of Science ®Google Scholar
• BIRNBAUMER M: Vasopressin receptor mutations and nephrogenic diabetes insipidus. Arch. Med. Res. (1999) 30:465–474.
   PubMed Web of Science ®Google Scholar
• KNOERS NV, DEEN PM: Molecular and cellular defects in nephrogenic diabetes insipidus. Pediatr. Nephrol (2001) 16:1146–1152.
   PubMed Web of Science ®Google Scholar
• MORELLO JP, BICHET DG: Nephrogenicdiabetes insipidus. Ann. Rev Physiol (2001) 63:607–630.
   PubMed Web of Science ®Google Scholar
• DRYJA T1 LI T: Molecular genetics of retinitis pigmentosa. Hum. Mal Genet. (1995) 4:1739–1743.
   PubMed Web of Science ®Google Scholar
• SUNG CH, MAKINO C, BAYLOR D, NATHANS J: A rhodopsin gene mutation responsible for autosomal dominant retinitis pigmentosa results in a protein that is defective in localization to the photoreceptor outer segment. J. Neurosci. (1994) 14:5818–5833.
   PubMed Web of Science ®Google Scholar
• LI T, SNYDER WK, OLSSON JE, DRYJA TP: Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments. Proc. Natl. Acad. Sri. USA (1996) 93:14176–14181.
   PubMed Web of Science ®Google Scholar
• DERETIC D, PULEO-SCHEPPKE B, TRIPPE C: Cytoplasmic domain of rhodopsin is essential for post- Golgi vesicle formation in a retinal cell-free system. J. Biol. Chem. (1996) 271:2279–2286.
   PubMed Web of Science ®Google Scholar
• MAYA-NO&EZ G, JANOVICK JA, ULLOA-AGUIRRE A, SODERLUND D, CONN PM, MENDEZ JP: Molecular basis of hypogonadotropic hypogonadism: restoration of mutant (E90K) GnRH receptor function by a deletion at a distant site. J. Clin. Endocnhol. Metab. (2002) 87:2144–2149.
   PubMed Web of Science ®Google Scholar
• JANOVICK JA, MAYA-NO&EZ G, CONN PM: Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J. Clin. Endocrinol Metab. (2002) 87:3255–3262.
   PubMed Web of Science ®Google Scholar
• ••First study showing pharmacologicalrescue of misfolded naturally-occurring hGnRHR mutations.
   Google Scholar
• PATEL DD, LELLI N, GARUTI R et al.:Analysis of two duplications of the LDL receptor gene affecting intracellular transport, catabolism, and surface binding of the LDL receptor. J. Lipid. Res. (1998) 39:1466–1475.
   PubMed Web of Science ®Google Scholar
• TAMARAPPOO BK, VERKMAN AS: Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J. Chu. Invest. (1999) 101:2257–2267.
   Web of Science ®Google Scholar
• SODERLUND D, CANTO P, DE LA CHESNAYE E, ULLOA-AGUIRRE A, MENDEZ JP: A novel homozygous mutation in the second transmembrane domain of the gonadotropin releasing hormone receptor gene. Chu. Endocrinol (04) (2001) 54:493–498.
   PubMed Web of Science ®Google Scholar
• SATO S, WARD CL, KROUSE ME, WINE JJ, KOPITO RR: Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. _J. Biol. Chem. (1996) 271:635–638.
   PubMed Web of Science ®Google Scholar
• CHENG SH, FANG SL, ZABNER J et al:Functional activation of the cystic fibrosis trafficking mutant AF508-CFTR by overexpression. Am. J. Physiol (1995) 268:L615–L624.
   PubMed Web of Science ®Google Scholar
• BROWN CR, HONG-BROWN LQ, WELCH WJ: Correcting temperature-sensitive protein folding defects. J. Chu. Endocrinol Metab. (1997) 99:1432–1444.
   Google Scholar
• MATSUDA S, SUZUKI-FUJIMOTO T, MINOWA A, UENO H, KATAMURA K, KOYASU S: Temperature-sensitive ZAP70 mutants degrading through a proteasome-independent pathway. Restoration of a kinase domain mutant by Cdc37. J. Biol. Chem (1999) 274:34515–34518.
   Google Scholar
• ZHOU Z, GONG Q, JANUARY CT: Correction of defective protein-trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. _J. Biol. Chem. (1999) 274:31123–31126.
   PubMed Web of Science ®Google Scholar
• MORELLO JP, SALAHPOUR A, LAPERRIERE A et al: Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Chit. Invest. (2000) 105:887–895.
   PubMed Web of Science ®Google Scholar
• ••Proposal of a model by which V2Rantagonists rescue incompletely folded mutant receptors.
   Google Scholar
• SCHDLEIN R, ZDHLKE K, KRAUSE G, ROSENTHAL W: Functional rescue of the nephrogenic diabetes insipidus-causing vasopressin V2 receptor mutants G185C and R202C by a second site suppressor mutation. J. Biol. Chem. (2001) 276:8384–8392.
   PubMed Web of Science ®Google Scholar
• PETAJA-REPO UE, HOGUE M, BHALLA S, LAPERRIERE A, MORELLO JP, BOUVIER M: Ligands act as pharmacological chaperones and increase the efficiency of 8 opioid receptor maturation. EMBO J. (2002) 21:1628–1637.
   PubMed Web of Science ®Google Scholar
• ••Demonstration that GPCR biosynthesiscan be pharmacologically-modulated at the ER level.
   Google Scholar
• SUNG CH, SCHNEIDER BG, AGARWAL N, PAPERMASTER DS, NATHANS J: Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Proc. Nat] Acad. Sri. USA (1991) 88:8840–8844.
   PubMed Web of Science ®Google Scholar
• PETAJA-REPO UE, HOGUE M, LAPERRIERE A, WALKER P, BOUVIER M: Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human 8 opioid receptor. j Biol. Chem. (2000) 275:13727–13736.
   PubMed Web of Science ®Google Scholar
• PETAJA-REPO UE, HOGUE M, LAPERRIERE A, BHALLA S, WALKER P, BOUVIER M: Newly synthesized human 8 opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome. j Biol. Chem. (2001) 276:4416–4423.
   PubMed Web of Science ®Google Scholar
• •Study demonstrating that a large proportion of newly synthesised, misfolded wild-type GPCRs are normally degraded by proteasomes.
   Google Scholar
• ASHTON WT, SISCO RIVI, YANG YT et al.: Potent nonpeptide GnRH receptor antagonists derived from substituted indole-5-carboxamides and -acetamides bearing a pyridine side-chain terminus. Bioorg. Med. Chem. Lett. (2001) 11:1727–1731.
   PubMed Web of Science ®Google Scholar
• ASHTON WT, SISCO RIVI, YANG YT et al.: Substituted indole-5-carboxamides and -acetamides as potent nonpeptide GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2001) 11:1723–1726.
   PubMed Web of Science ®Google Scholar
• ASHTON WT, SISCO RIVI, KIECZYKOWSKI GR et al.: Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity. Bioorg. Med. Chem. Lett. (2001) 11:2597–2602.
   PubMed Web of Science ®Google Scholar
• LEASIOS-MIRANDA A, JANOVICK JA, CONN PM: Receptor-misrouting: an unexpectedly prevalent and rescuable etiology in GnRHR-mediated hypogonadotropic hypogonadism. I Chu. Endocrinol Metab. (2002) 87:4825–4828.
   PubMed Web of Science ®Google Scholar
• LEASIOS-MIRANDA A, JANOVICK JA, MAYA-NO&EZ G, ULLOA-AGUIRRE A, CONN PM: Misrouted proteins as a novel disease etiology and therapeutic target: rescue of hypogonadotropic hypogonadism-causing and manufactured gonadotropin-releasing hormone receptor mutants as a proof of principle. In: Molecular Endocrinology: Methods and Protocols. Kumar R (Ed.), Humana Press, Totowa, New Jersey (2003). In Press.
   Google Scholar
• VRECL M, ANDERSON L, HANYALOGLU A et al.: Agonist-induced endocytosis and recycling of the gonadotropin-releasing hormone receptor: effect of P-arrestin on internalization kinetics. Ma Endocrinol (1998) 12:1818–1829.
   PubMedGoogle Scholar
• MYBURGH DB, PAWSON AJ, DAVIDSON JS, FLANAGAN CA, MILLER RP, HAPGOOD JP: A single amino acid substitution in transmembrane helix VI results in overexpression of the human GnRH receptor. Eur. Endocrinol (1998) 139:438–447.
   Web of Science ®Google Scholar
• PRALONG FP, GOMEZ F, CASTILLO E et al: Complete hypogonadotropic hypogonadism associated with a novel inactivating mutation of the gonadotropin-releasing hormone receptor. aP Chit. Endocrinol. Metab. (1999) 84:3811–3816.
   PubMed Web of Science ®Google Scholar
• JANOVICK J, GOULET M, BUSH E, GREER J, WETTLAUFFER D, CONN P.M: Chemical characteristics of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. P Pharmacol Exp. Ther. (2003). In Press.
   Google Scholar